Business, energy, technology, markets and global industry news from Business News Today

Hunter syndrome

PharmaDeviceNews Hunter syndrome
JCR Pharmaceuticals’ IZCARGO UAE marketing authorization expands access to a blood-brain barrier-penetrating enzyme replacement therapy for Hunter syndrome. Representative image.
Pharma & Biotech

JCR’s enzyme therapy reaches Kuwait. Can crossing the blood-brain barrier change Hunter syndrome care?

JCR Pharmaceuticals has received conditional marketing authorization for IZCARGO in Kuwait, its second market outside Japan. The blood-brain barrier-penetrating enzyme therapy is designed to address both systemic and neurological features of Hunter syndrome, although its global Phase 3 programme remains ongoing.

Read More
JCR Pharmaceuticals’ IZCARGO UAE marketing authorization expands access to a blood-brain barrier-penetrating enzyme replacement therapy for Hunter syndrome. Representative image.
Pharma & Biotech

IZCARGO has moved beyond Japan, but JCR Pharmaceuticals’ real test begins after the UAE authorization

JCR Pharmaceuticals’ UAE authorization for IZCARGO opens a new market, but reimbursement, supply and Phase III evidence will shape its impact.

Read More
A scientist reviews brain imaging and neurological research data as Denali Therapeutics channels its $195 million FDA voucher proceeds into blood-brain barrier drug development and the TransportVehicle pipeline. Representative image.
Pharma & Biotech

Denali monetises its FDA voucher as AVLAYAH enters a critical confirmatory phase

Denali Therapeutics is converting AVLAYAH’s regulatory reward into non-dilutive capital for its blood-brain barrier pipeline, but clinical and commercial risks remain.

Read More
Pharma & Biotech

Is JCR unlocking the CNS for lysosomal storage diseases before gene therapy gets there?

Find out how JCR Pharmaceuticals is redefining lysosomal disease therapy with brain-targeted delivery platforms.

Read More